Despite the situation of COVID-19, We still wanted to honor our commitment and did a draw for the travel lottery and broadcast everything via a FACEBOOK LIVE broadcast… Thank you for your participation! https://www.facebook.com/ataxie.canada/ I suggest you ’follow’ ’and like’ our page! Congratulations to our winners for the prizes of...
Late-onset hereditary dominant episodic ataxia in French Canadians Dr David Pellerin 1, Dr. Mathilde Renaud 2, Mrs. Karine Choquet 1, Prof. Martine Tétreault 3, Mrs. Sylvie Provost 3, Mrs. Marie-Josée Dicaire 1, Dr Roberta La Piana 1, Dr Rami Massie 1, Dr Colin Chalk 1, Dr. Anne-Louise Lafontaine 1, Prof. Marie-Pierre...
Gene editing of human hematopoietic stem and progenitor cells for Friedreich’s ataxia using CRISPR/Cas9 technology Dr. Celine Rocca 1, Ms. Shi Yanmeng 1, Mr. Jay Sharma 1, Dr. Prashant Mali 1, Dr. Stephanie Cherqui 1 University of California, San Diego Our goal is now to develop an autologous HSPC...
Friedreich Ataxia Collaborative Clinical Research Network and Natural History Research Project We want to inform you that Dr. Antoine Duquette, a neurologist at the CHUM, and his research team will now be responsible for a site in Montreal that integrates the Collaborative Research Network in Friedreich Ataxia (CCRN in FA)...
ACHIEVED PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT IMPROVEMENT IN MFARS COMPARED TO PLACEBO AFTER 48 WEEKS OF TREATMENT Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, announced today that the registrational Part 2 portion of the MOXIe Phase 2 trial of omaveloxolone in patients with Friedreich’s ataxia (FA) met its...
Mataró, Barcelona, Spain and Charleroi, Belgium, October 8, 2019 – Minoryx Therapeutics, a company specializing in the development of innovative treatments for orphan central nervous system (CNS) diseases, today announces that it has completed recruitment in the FRAMES phase 2 clinical trial of its novel PPARγ agonist, leriglitazone (MIN-102), in patients...
Posted on: 2019-09-24 – Posted by: Ataxia Canada – Category: publications Deadline: October 24th, 2019 Dear Members, At the next annual general assembly on November 24th 2019, we will elect five (5) members to the Board of Directors. We are seeking to solicit nominations that satisfy some of...
